TG Therapeutics Inc

NASDAQ:TGTX   1:00:00 PM EDT
36.72
+0.43 (+1.18%)
4:42:48 PM EDT: $36.46 -0.26 (-0.71%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)5.83B
Current PE148.89
Forward PE 43.2
2yr Forward PE 20.98
See more stats
Estimates Current Quarter
Revenue$137.13 Million
Adjusted EPS$0.19
See more estimates
10-Day MA$36.50
50-Day MA$37.04
200-Day MA$32.59
See more pivots

TG Therapeutics Inc Stock, NASDAQ:TGTX

3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560
United States of America
Phone: +1.212.554.4484
Number of Employees: 338

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.